Compared to Estimates, Avantor (AVTR) Q3 Earnings: A Look at Key Metrics

For the quarter ended September 2025, Avantor, Inc. (AVTR) reported revenue of $1.62 billion, down 5.3% over the same period last year. EPS came in at $0.22, compared to $0.26 in the year-ago quarter.

The reported revenue represents a surprise of -1.56% over the Zacks Consensus Estimate of $1.65 billion. With the consensus EPS estimate being $0.23, the EPS surprise was -4.35%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Avantor performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Bioscience Production: $527.3 million compared to the $536.7 million average estimate based on four analysts. The reported number represents a change of -2.9% year over year.
• Revenue- Laboratory Solutions: $1.1 billion compared to the $1.11 billion average estimate based on four analysts. The reported number represents a change of -6.4% year over year.
• Adjusted Operating Income- Laboratory Solutions: $123.6 million compared to the $134.01 million average estimate based on two analysts.
• Adjusted Operating Income- Corporate: $-14 million versus the two-analyst average estimate of $-19.3 million.
• Adjusted Operating Income- Bioscience Production: $127.7 million compared to the $134.34 million average estimate based on two analysts.

View all Key Company Metrics for Avantor here>>>

Shares of Avantor have returned +20.8% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Avantor, Inc. (AVTR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research